According to Databao statistics, there are more than 700 institutional research companies in the past week, and carbon nanotube leader Tiannai Technology has become the stock with the largest number of research institutions, with a total of 440 institutions investigating the company. Other stocks with a large number of research institutions include Antu Biology, Guoxuan High-Tech, Hengxuan Technology, etc., all of which have more than 100 research institutions. It is worth mentioning that the new Zebang, Jiang Special Motor and other lithium industry chain also has more than 100 institutions to investigate. (Securities Times)
近一周机构调研公司数量有700多家
There are more than 700 institutional research companies in the past week.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.